THE NON ERGOT D2-DOPAMINE AGONIST CV-205-502 DECREASES GROWTH-HORMONECONCENTRATIONS IN ACROMEGALIC PATIENTS

It was the aim of this study to test for a possible effect of the new non ergot dopamine agonist CV 205-502 on plasma growth hormone(GH) con centrations in acromegaly. 10 acromegalic patients received a single o ral dose of 150 mu g CV 205-502 after an overnight fast. As a control group 7 acromegalic patients undertook the same procedure without rece iving any drug. Blood samples were drawn hourly up to 7 hours thereaft er for determination of GH. Plasma growth hormone concentrations decre ased by 48.8 +/- 8.7 %. The nadir was observed 3 hours after CV 205-50 2 was administered and GH concentrations remained suppressed throughou t the 7 hours of the test period. In contrast GH plasma concentrations in the control group remained stable. We conclude that acute administ ration of CV 205-502 supresses GH secretion in acromegalic patients an d thus could serve as an alternative therapy in acromegaly.